Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual MeetingGlobeNewsWire • 06/22/20
Find Strong Buy Stocks for the Coronavirus Market Rally with this ScreenerZacks Investment Research • 06/02/20
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/02/20
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 StudyGlobeNewsWire • 05/27/20
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation StudyGlobeNewsWire • 05/14/20
Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific ProgramGlobeNewsWire • 05/13/20
Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market FacilityGlobeNewsWire • 04/08/20